Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
- PMID: 24288529
- PMCID: PMC3833004
- DOI: 10.1155/2013/102120
Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
Abstract
Aims. To evaluate carotid intima-media thickness (cIMT) and biomarkers of the osteoprotegerin/receptor activator of nuclear factor- κ B ligand (OPG/RANKL) system in type 1 diabetes (T1DM) children and adolescents and controls. Subjects and Methods. Fifty six T1DM patients (mean ± SD age: 12.0 ± 2.7 years, diabetes duration: 5.42 ± 2.87 years and HbA1c: 8.0 ± 1.5%) and 28 healthy matched controls, were studied with anthropometric and laboratory measurements, including serum OPG, soluble RANKL (sRANKL) and cIMT. Results. Anthropometric, laboratory, and cIMT measurements were similar between T1DM youngsters and controls. However patients with longer diabetes duration (>/7.0 years) had indicatively higher cIMT (cIMT = 0.49 vs 0.44 mm, P 0.072) and triglyceride levels than the rest of the patients (93.7 vs 64.6 mg/dl, P 0.025). Both in the total study population (β 0.418, P 0.027) and among T1DM patients separately (β 0.604, P 0.013), BMI was the only factor associated with cIMT. BMI was further associated with OPG in both groups (β -0.335, P 0.003 and β -0.356, P 0.008 respectively), while sRANKL levels were not associated with any factor. Conclusions. BMI was the strongest independent predictor of cIMT among the whole population, and especially in diabetics, suggesting a possible synergistic effect of diabetes and adiposity on atherosclerotic burden. BMI was overall strongly associated with circulating OPG, but the causes of this association remain unclear.
Similar articles
-
Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction.J Pediatr Endocrinol Metab. 2018 Nov 27;31(11):1169-1177. doi: 10.1515/jpem-2018-0147. J Pediatr Endocrinol Metab. 2018. PMID: 30352039
-
Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.Osteoporos Int. 2016 Apr;27(4):1631-1643. doi: 10.1007/s00198-015-3422-5. Epub 2015 Nov 20. Osteoporos Int. 2016. PMID: 26588909
-
Relationships between osteoprotegerin, receptor activator of the nuclear factor kB ligand serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus.Panminerva Med. 2014 Sep;56(3):221-5. Panminerva Med. 2014. PMID: 25056244
-
Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.Eur J Endocrinol. 2011 Jan;164(1):61-8. doi: 10.1530/EJE-10-0720. Epub 2010 Oct 25. Eur J Endocrinol. 2011. PMID: 20974706
-
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31. doi: 10.1210/jc.2005-0794. Epub 2005 Aug 16. J Clin Endocrinol Metab. 2005. PMID: 16105967 Review.
Cited by
-
OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.Ital J Pediatr. 2019 Dec 10;45(1):161. doi: 10.1186/s13052-019-0748-1. Ital J Pediatr. 2019. PMID: 31823791 Free PMC article.
-
Circulating calcification inhibitors are associated with arterial damage in pediatric patients with primary hypertension.Pediatr Nephrol. 2021 Aug;36(8):2371-2382. doi: 10.1007/s00467-021-04957-5. Epub 2021 Feb 18. Pediatr Nephrol. 2021. PMID: 33604725 Free PMC article.
-
Phenolic constituents and modulatory effects of Raffia palm leaf (Raphia hookeri) extract on carbohydrate hydrolyzing enzymes linked to type-2 diabetes.J Tradit Complement Med. 2017 Feb 4;7(4):494-500. doi: 10.1016/j.jtcme.2017.01.003. eCollection 2017 Oct. J Tradit Complement Med. 2017. PMID: 29034198 Free PMC article.
-
Comparison of novel markers of metabolic complications and cardiovascular risk factors between obese non-diabetic and obese type 1 diabetic children and young adults.Front Endocrinol (Lausanne). 2022 Dec 12;13:1036109. doi: 10.3389/fendo.2022.1036109. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36578961 Free PMC article.
-
Chlorophytum borivilianum root extract maintains near normal blood glucose, insulin and lipid profile levels and prevents oxidative stress in the pancreas of streptozotocin-induced adult male diabetic rats.Int J Med Sci. 2014 Sep 3;11(11):1172-84. doi: 10.7150/ijms.9056. eCollection 2014. Int J Med Sci. 2014. PMID: 25249786 Free PMC article.
References
-
- Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis. Can we, does it matter, and should we? Journal of the American College of Cardiology. 2010;56(2):98–105. - PubMed
-
- Järvisalo MJ, Jartti L, Näntö-Salonen K, et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation. 2001;104(24):2943–2947. - PubMed
-
- Dahl-Jørgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia. 2005;48(8):1445–1453. - PubMed
-
- Pozza RD, Bechtold S, Bonfig W, et al. Age of onset of type 1 diabetes in children and carotid intima medial thickness. Journal of Clinical Endocrinology and Metabolism. 2007;92(6):2053–2057. - PubMed
-
- McVeigh GE, Gibson W, Hamilton PK. Cardiovascular risk in the young type 1 diabetes population with a low 10-year, but high lifetime risk of cardiovascular disease. Diabetes, Obesity and Metabolism. 2013;15(3):198–203. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources